Navigating an NIH Gene Therapy Trial
Lynndrick Holmes shares his battle with sickle cell disease
On March 21, 2024, the CTSI Community Engagement & Research Program (CERP) was honored to have a powerful and overwhelmingly successful discussion with Lynndrick Holmes regarding his journey to fight an invisible disease while navigating challenges within the US health system. Moderated by CERP team member Ejiro Ntekume, Mr. Holmes discussed entrusting his health and faith in a lifesaving clinical trial with the National Institutes of Health (NIH) that reverted his chronic sickle cell disease.
Lynndrick also provided helpful insight for healthcare provider and others in the audience, stating: "Lean on the science." He expressed the importance of providers approaching patient medical concerns scientifically. He also parted with hopes of cultural humility being more prevalent in health care delivery with the understanding that everyone responds to pain differently.
Learn more about Mr. Holmes' journey published in the NY Times.
Image source: UCLA CTSI CERP
Related Articles
The NIH continues to support training populations from underrepresented groups
As national and state policies evolve, the NIH remains committed to promoting pathways for potential trainees from all backgrounds.
Junior investigator Matthew Anderson receives Diversity Supplement from NIH
One way in which the National Institutes of Health (NIH) endeavors to be more inclusive is through its Diversity Supplement mechanism
Lundquist immunologist and former KL2 scholar receives K01 grant to advance infectious disease research
Dr. Shakti Singh's research will study the role of HIL proteins in C. auris virulence
Researchers use machine learning to identify patients at risk of vision loss due to diabetic retinopathy
Researchers at Charles Drew University use artificial intelligence to predict risk of diabetic retinopathy in South LA community.